Ad Comm review Wednesday on Puma's neratinib in HER2-positive breast cancer; shares up 3% premarket

|About: Puma Biotechnology, Inc. (PBYI)|By:, SA News Editor

The FDA's Oncologic Drug Advisory Committee will meet on Wednesday, May 24, to discuss Puma Biotechnology's (NYSE:PBYI) New Drug Application (NDA) seeking approval of neratinib for the treatment of HER2+ breast cancer. Shares are up 3% premarket ahead of the release of briefing docs.

Subscribe for full text news in your inbox